【医药】坚定看好医药板块回暖，重申投资临床价值三段论——医药生物行业跨市场周报（20260301）（黎一江/吴佳青/黄素青/曹聪聪/叶思奥）

Market Overview - The A-share pharmaceutical and biotechnology index increased by 0.50% last week, underperforming the CSI 300 index by 0.58 percentage points and the ChiNext index by 1.82 percentage points, ranking 25th among 31 sub-industries [4] - The Hong Kong Hang Seng Healthcare Index fell by 6.07%, underperforming the Hang Seng Index by 4.96 percentage points [4] R&D Progress - Last week, several clinical applications were newly undertaken, including CMS-D008 injection by Kangzhe Pharmaceutical and KC1036 tablets by Kangchen Pharmaceutical [4] - Other IND applications included HSK46575 tablets by Haishi Pharmaceutical, injection of Lankangyilong monoclonal antibody by Bailitianheng, and injection of BL-M11D1 [4] - Notable ongoing clinical trials include ICP-538 by Nocera Biopharma and DC6001 by China Resources Sanjiu in Phase I, HLX43 by Fuhong Hanlin and Punanli monoclonal antibody by Tianjing Biopharma in Phase II, and SYH2053 and SYS6010 by Shiyao Group in Phase III [4] Investment Outlook - The company maintains a positive outlook on the pharmaceutical sector's recovery, reiterating the investment thesis based on the three stages of clinical value: 1. "0→1" technological breakthroughs in innovative drugs, particularly in oncology, weight loss, and autoimmune diseases, as well as advancements in innovative medical devices like brain-machine interfaces [5] 2. "1→10" clinical validation with high-quality domestic innovative drugs accelerating overseas authorization and the rise of high-end medical devices [5] 3. "10→100" efficiency in China, where CXO companies leverage low costs and high efficiency to build competitive advantages, particularly in the disposable medical supplies sector [5] - The focus is on the accelerated overseas expansion of innovative drugs and their upstream CXO, as well as the innovation and upgrade of high-end medical devices and high-value consumables [5]